Addington, J, Addington, D (2007). Patterns, predictors and impact of substance use in early psychosis: a longitudinal study. Acta Psychiatrica Scandinavia
115, 304–309.
Barbeito, S, Vega, P, Ruiz de Azua, S, Saenz, M, Martinez-Cengotitabengoa, M, Gonzalez-Ortega, I, Bermudez, C, Hernanz, M, Corres, BF, Gonzalez-Pinto, A (2013). Cannabis use and involuntary admission may mediate long-term adherence in first-episode psychosis patients: a prospective longitudinal study. BMC Psychiatry
13, 326.
Beards, S, Gayer-Anderson, C, Borges, S, Dewey, ME, Fisher, HL, Morgan, C (2013). Life events and psychosis: a review and meta-analysis. Schizophrenia Bulletin
39, 740–747.
Borenstein, M, Hedges, LV, Higgins, JP, Rothstein, HR (2011). Introduction to Meta-analysis. Wiley.
Buckley, PF (2007). Prevalence and consequences of the dual diagnosis of substance abuse and severe mental illness. Journal of Clinical Psychiatry
67, 5–9.
Buckley, PF, Wirshing, DA, Bhushan, P, Pierre, JM, Resnick, SA, Wirshing, WC (2007). Lack of insight in schizophrenia: impact on treatment adherence. CNS Drugs
21, 129–141.
Castberg, I, Andreas, AW, Olav, S (2009). Does level of care, sex, age, or choice of drug influence adherence to treatment with antipsychotics?
Journal of Clinical Psychopharmacology
29, 415–420.
Coldham, E, Addington, J, Addington, D (2002). Medication adherence of individuals with a first episode of psychosis. Acta Psychiatrica Scandinavica
106, 286–290.
Colom, F, Vieta, E, Tacchi, MJ, Sanchez-Moreno, J, Scott, J (2005). Identifying and improving non-adherence in bipolar disorders. Bipolar Disorders
7, 24–31.
Conrod, P, Castellanos-Ryan, N, Strang, J (2010). Brief personality-targeted coping skills interventions and survival as a non-drug user over a 2-year period. Archive General Psychiatry
67, 85–93.
Cramer, JA, Rosenheck, R (1998). Compliance with medication regimen for mental and physical disorders. Psychiatric Services
49, 196–201.
de Haan, L, van Amelsvoort, T, Dingemans, P, Linszen, P (2007). Risk factors for medication non-adherence in patients with first episode schizophrenia and related disorders; a prospective five year follow-up. Pharmacopsychiatry
40, 264–268.
DerSimonian, R, Laird, N (1986). Meta-analysis in clinical trials. Controlled Clinical Trials
7, 177–188.
Egger, M, Davey Smith, G, Schneider, M, Minder, C (1997). Bias in meta-analysis detected by a simple, graphical test. British Medical Journal (Clinical Research Edition)
315, 629–634.
Faridi, K, Joober, R, Malla, A (2012). Medication adherence mediates the impact of sustained cannabis use on symptom levels in first-episode psychosis. Schizophrenia Research
141, 78–82.
Fenton, WS, Blyler, CR, Heinsse, RK (1997). Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schizophrenia Bulletin
23, 637–651.
Foti, DJ, Kotov, R, Guey, LT, Bromet, EJ (2010). Cannabis use and the course of schizophrenia: 10-year follow-up after first hospitalization. American Journal of Psychiatry
167, 987–993.
Gonzalez-Pinto, A, Mosquera, F, Alonso, M, Lòpez, P, Ramìrez, F, Vieta, E, Baldessarini, RJ (2006). Suicidal risk in bipolar I disorder patients and adherence to long-term lithium treatment. Bipolar Disorders
8, 618–624.
Gonzalez-Pinto, A, Reed, C, Novick, D, Bertsch, J, Haro, JM (2010). Assessment of medication adherence in a cohort of patients with bipolar disorder. Pharmacopsychiatry
43, 263–270.
Grech, A, Van Os, J, Jones, PB, Lewis, SW, Murray, RM (2005). Cannabis use and outcome of recent onset psychosis. European Psychiatry
20, 349–353.
Green, AI (2006). Pharmacotherapy for schizophrenia and co-occurring substance use disorders. Neurotoxicity Research
11, 33–39.
Green, B, Young, R, Kavanagh, D (2005). Cannabis use and misuse prevalence among people with psychosis. British Journal of Psychiatry
187, 306–313.
Higashi, K, Medic, G, Littlewood, KJ, Diez, T, Granström, O, De Hert, M (2013). Medication Adherence in schizophrenia: factors influencing adherence and consequences of nonadherence, a systematic literature review. Therapeutic Advances in Psychopharmacology
3, 200–218.
Higgins, JP, Thompson, SG, Deeks, JJ, Altman, DG (2003). Measuring inconsistency in meta-analyses. British Medical Journal (Clinical Research Edition)
327, 557–560.
Jónsdóttir, H, Opjordsmoen, S, Birkenaes, A, Simonsen, C, Engh, J, Ringen, P, Vaskinn, A, Friis, S, Sundet, K, Andreassen, O (2013). Predictors of medication adherence in patients with schizophrenia and bipolar disorder. Acta Psychiatrica Scandinavica
127, 23–33.
Julius, RJ, Novitsky, MA Jr., Dubin, WR (2009). Medication adherence: a review of the literature and implications for clinical practice. Journal of Psychiatric Practice
15, 34–44.
Kampman, O, Lehtinen, K (1999). Compliance in psychoses. Acta Psychiatrica Scandinavia
100, 167–175.
Keith, SJ, Kane, JM (2003). Partial compliance and patient consequences in schizophrenia: our patients can do better. Journal of Clinical Psychiatry
64, 1308–1315.
Koskinen, J, Lohonen, J, Koponen, H, Isohanni, M, Miettunen, J (2010). Rate of cannabis use disorders in clinical samples of patients with schizophrenia: a meta-analysis. Schizophrenia Bulletin
36, 1115–1130.
Kovasznay, B, Fleischer, J, Tanenberg-Karant, M, Jandorf, L, Miller, AD, Bromet, E (1997). Substance use disorder and the early course of illness in schizophrenia and affective psychosis. Schizophrenia Bulletin
23, 195–201.
Lacro, JP, Dunn, LB, Dolder, CR, Leckband, SG, Jeste, DV (2002). Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. Journal of Clinical Psychiatry
63, 892–909.
Large, M, Sharma, S, Compton, MT, Slade, T, Nielssen, O (2011). Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Archive General Psychiatry
68, 555–561.
Linszen, DH, Dingemans, PM, Lenior, ME (1994). Cannabis abuse and the course of recent-onset schizophrenic disorders. Archives of General Psychiatry
51, 273–279.
Liraud, F, Verdoux, H (2001). Association between temperamental characteristics and medication adherence in subjects presenting with psychotic or mood disorders. Psychiatry Research
102, 91–95.
Martinez-Arevalo, MJ, Calcedo-Ordonez, A, Varo-Prieto, JR (1994). Cannabis consumption as a prognostic factor in schizophrenia. British Journal of Psychiatry
164, 679–681.
Martinez-Ortega, JM, Gutierrez-Rojas, L, Jurado, D, Higueras, A, Diaz, FJ, Gurpegui, M (2012). Factors associated with frequent psychiatric admissions in a general hospital in Spain. International Journal of Social Psychiatry
58, 532–535.
McGrath, J, Saha, S, Welham, J, El Saadi, O, MacCauley, C, Chant, D (2004). A systematic review of the incidence of schizophrenia: the distribution of rates and the influence of sex, urbanicity, migrant status and methodology. BMC Medicine
2, 1.
Miller, R, Ream, G, McCormack, J, Gunduz-Bruce, H, Sevy, S, Robinson, D (2009). A prospective study of cannabis use as a risk factor for non-adherence and treatment dropout in first-episode schizophrenia. Schizophrenia Research
113, 138–144.
Mojtabai, R, Lavelle, J, Gibson, PJ, Sohler, NL, Craig, TJ, Carlson, GA (2002). Gaps in Use of Antipsychotics after discharge by first-admission patients with schizophrenia, 1989 to 1996. Psychiatric Services
53, 337–339.
Moore, THM, Zammit, S, Lingford-Hughes, A, Barnes, TR, Jones, PB, Burke, M, Lewis, G (2007). Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet
370, 319–328.
Mutsatsa, SH, Joyce, EM, Hutton, SB, Webb, E, Gibbins, H, Paul, S, Barnes, TR (2003). Clinical correlates of early medication adherence: west London first episode schizophrenia study. Acta Psychiatrica Scandinavia
108, 439–446.
Nosè, M, Barbui, C, Tansella, M (2003). How often do patients with psychosis fail to adhere to treatment programs? A systematic review. Psychological Medicine
33, 1149–1160.
Penttila, M, Jaaskelainen, E, Hirvonen, N, Isohanni, M, Miettunen, J (2014). Duration of untreated psychosis as predictor of long-term outcome in schizophrenia: systematic review and meta-analysis. British Journal of Psychiatry
205, 88–94.
Perkins, DO, Johnson, JL, Hamer, RM, Zipursky, RB, Keefe, RS, Centorrhino, F, Green, AI, Glick, IB, Kahn, RS, Sharma, T (2006). Predictors of antipsychotic medication adherence in patients recovering from a first psychotic episode. Schizophrenia Research
83, 53–63.
Pogge, DL, Singer, MB, Harvey, PD (2005). Rates and predictors of adherence with atypical antipsychotic medication: a follow-up study of adolescent inpatients. Journal of Child & Adolescent Psychopharmacology
15, 901–912.
Reed, RA, Harrow, M, Herbener, ES, Martin, EM (2002). Executive function in schizophrenia: is it linked to psychosis and poor life functioning?
Journal of Nervous Mental Disorders
190, 725–732.
Rehman, IU, Farooq, S (2007). Schizophrenia and comorbid self reported cannabis abuse: impact on course, functioning and services use. Journal of the Pakistan Medical Association
57, 60.
Schimmelmann, B, Conus, P, Cotton, S, Kupferschmid, S, McGorry, P, Lambert, M (2012). Prevalence and impact of cannabis use disorders in adolescents with early onset first episode psychosis. European Psychiatry
27, 463–469.
Schoeler, T, Monk, A, Sami, MB, Klamerus, E, Foglia, E, Brown, R, Murray, R, Camuri, G, Altamura, AC, Murray, R, Bhattacharyya, S (2016
a). Continued versus discontinued cannabis use in patients with psychosis: a systematic review and meta-analysis. Lancet Psychiatry
3, 215–225.
Schoeler, T, Petros, N, Di Forti, M, Pingault, JB, Klamerus, E, Foglia, E, Small, A, Murray, R, Bhattacharyya, S (2016
b). Association between continued cannabis use and risk of relapse in first-episode psychosis: a quasi-experimental investigation within an observational study. JAMA Psychiatry
73, 1173–1179.
Sendt, KV, Tracy, DK, Bhattacharyya, S (2014). A systematic review of factors influencing adherence to antipsychotic medication in schizophrenia-spectrum disorders. Psychiatry Research
225, 14–30.
Sharma, T, Antonova, L (2003). Cognitive function in schizophrenia: deficits, functional consequences, and future treatment. Psychiatric Clinicas of North America
26, 25–40.
Strakowski, SM, DelBello, MP, Fleck, DE, Adler, CM, Anthenelli, RM, Keck, PE, Arnold, LM, Amicone, J (2007). Effects of co-occurring cannabis use disorders on the course of bipolar disorder after a first hospitalization for mania. Archives of General Psychiatry
64, 57–64.
Stroup, DF, Berlin, JA, Morton, SC, Olkin, I, Williamson, GD, Rennie, D, Moher, D, Becker, BJ, Sipe, TA, Thacker, SB (2000). Meta-analysis of observational studies in epidemiology: a proposal for reporting. Journal of the American Medical Association
283, 2008–2012.
Swann, AC, Dougherty, DM, Pazzaglia, PJ, Pham, M, Moeller, FG (2004). Impulsivity: a link between bipolar disorder and substance abuse. Bipolar Disorders
6, 204–212.
Van Dijk, D, Koeter, MWJ, Hijman, R, Kahn, RS, van den Brink, W (2012). Effect of cannabis use on the course of schizophrenia in male patients: a prospective cohort study. Schizophrenia Research
37, 50–57.
Velligan, DI, Lam, YW, Glahn, DC, Barrett, JA, Maples, NJ, Ereshefsky, L, Miller, AL (2006). Defining and assessing adherence to oral antipsychotics: a review of the literature. Schizophrenia Bulletin
32, 724–742.
Wilson, RP, Bhattacharyya, S (2016). Antipsychotic efficacy in psychosis with co-morbid cannabis misuse: a systematic review. Journal of Psychopharmacology
30, 99–111.
Zammit, S, Moore, THM, Lingford-Hughes, A, Barnes, TR, Jones, PB, Burke, M (2008). Effects of cannabis use on outcomes of psychotic disorders: systematic review. British Journal of Psychiatry
193, 357–363.
